Vendor Intelligence Report: Skye Peptides

Published 12 Jun 2026. 26-page investigative report on who is behind Skye Peptides: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Skye Peptides is a product-specific vendor, not a simple yes/no call. Across 75 Finnrick lab tests, the overall record is 42 pass / 33 fail — overall pass rate 56%. The split is sharp: semaglutide, tirzepatide and retatrutide are the more defensible lanes, while BPC-157 is the central caution signal. The methodology-sensitivity work shows ratings move under stricter lenses, but the durable finding is unevenness across the catalog.

The operating surface looks more mature than the accountability surface. The storefront uses Cloudflare gating, WordPress/WooCommerce indicators, Google Workspace, Klaviyo, Zendesk-linked mail and other non-throwaway infrastructure. Against that, Skye Research/Skye Peptides did not resolve to a California entity record in the searches performed, the listed Los Angeles address maps to a virtual-office/coworking provider, and no named principals were identified.

Skye’s COA footprint is a real positive: public Janoshik/COA pathways and third-party test records give buyers more to verify than screenshot-only vendors. The limit is equally important: those records verify submitted samples, not vial-level consistency, manufacturing location, or the vendor’s broader US-manufacturing and in-house-lab claims.

The brand also has an external trust problem. Investigators mapped at least five lookalike or impersonation domains using Skye naming or address cues, alongside a small discount-code ecosystem where most visible code/link promotion lacked clear disclosure. Public reputation is relatively favorable and price-premium positioning is consistent, but neither substitutes for product-specific lab data and domain verification.

Inside the full report:

  • Product-by-product Finnrick results, methodology-divergence charts and rating trajectories for all 10 tested products
  • California SOS/OpenCorporates searches, address analysis and ownership-surface findings
  • Clone-site network map separating the official domain from typo, labs, shop and LLC-style lookalikes
  • COA and manufacturing-claims review using Disclosed Labs, Janoshik and Peptigrity artifacts
  • RDAP/DNS/infrastructure fingerprint covering Cloudflare, WooCommerce/WordPress, Klaviyo, Zendesk, Mailgun and the origin-server lead
  • Affiliate and discount-code sweep across X, Reddit/forum posts and coupon aggregators, with disclosure assessment

Risk assessment

  • Product-specific quality risk in BPC-157, CJC-1295, Melanotan II, Survodutide and Tesamorelin — high: BPC-157 is 3/12 pass with a 35.96% rating; CJC-1295 is 2/7 at 26.51%, Melanotan II and Survodutide are 0/4, and Tesamorelin is 2/5.
  • Corporate accountability risk — high: Skye Research/Skye Peptides had no California SOS or California OpenCorporates record in the June 12, 2026 searches and uses a virtual-office address.
  • Copycat and brand-confusion risk — high: At least five lookalike/impersonation domains were found using the Skye name or address, while no authoritative anti-counterfeit or authorized-channel list was identified in the supplied captures.
  • Manufacturing-origin verification risk — medium: Skye's US-manufacturing/in-house-lab claims were not corroborated by public facility records; Janoshik/COA verification confirms tested samples, not production origin.
  • Undisclosed affiliate-promotion risk — medium: The promotion scan found seven code/link promoters and only one clear disclosure, including repeated X posts recommending Skye with the exploring peptides code.